DelveInsight’s “Osteosarcoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Osteosarcoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Osteosarcoma Market Forecast
Some of the key facts of the Osteosarcoma Market Report:
- The Osteosarcoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- The US reports about 800 new instances of osteosarcoma annually, according to Johns Hopkins University (2023). There are about 400 of these cases that affect children and teenagers
- According to Gabriela A. Rojas (2021), 20% to 40% of all bone malignancies are osteosarcomas. 80% is the average 5-year overall survival rate for people with localised OS
- DelveInsight analysts estimate that 2,200 people will be newly diagnosed with osteosarcoma overall in the 7MM in 2022
- According to the projections, there will be approximately 1,100 new cases of osteosarcoma in the United States in 2022
- Numerous businesses, including , are working on treatments for the treatment of people with osteosarcomaEisai (Lenvatinib), Bayer (BAY80-6946), MedPacto (Vactosertib), Zentalis Pharmaceuticals (Azenosertib), and Hutchmed (Surufatinib)
- Key Osteosarcoma Companies: Eisai, Y-mAbs Therapeutics, Bayer, MedPacto, Zentalis Pharmaceuticals, Hutchmed, AstraZeneca, Pfizer, Merck Sharp & Dohme LLC, George Clinical Pty Ltd, Immunex/Berlex, Eli Lilly and Company, Isofol Medical AB, Bristol-Myers Squibb, Novartis, Eleison Pharma, Genentech, Inc., Ariad Pharma, Inex Pharma, and others
- Key Osteosarcoma Therapies: Lenvatinib, Naxitamab, BAY80-6946, Vactosertib, Azenosertib, Surufatinib, Olaparib, ZN-c3, Avelumab, Lenvatinib, OST31-164, Ifosfamide, Pemetrexed, Calcium Folinate, Nivolumab, RAD001, nhaled Lipid Cisplatin (ILC), Cisplatin, ridaforolimus, Liposomal Vincristine, and others
- The Osteosarcoma epidemiology based on gender analyzed that males contributes to higher incident cases as compared to females
- The Osteosarcoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteosarcoma pipeline products will significantly revolutionize the Osteosarcoma market dynamics.
Osteosarcoma Overview
The most prevalent kind of bone cancer that typically arises in the osteoblast cells of the bone is osteosarcoma (osteogenic sarcoma). Most frequently, it affects the long bones near the knee. The lower leg, upper arm bone, upper leg, thighbone, or any other bone in the body—including those in the pelvis, shoulder, and skull—are other sites.
Get a Free sample for the Osteosarcoma Market Report
https://www.delveinsight.com/report-store/osteosarcoma-market
Osteosarcoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Osteosarcoma Epidemiology Segmentation:
The Osteosarcoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Osteosarcoma
- Prevalent Cases of Osteosarcoma by severity
- Gender-specific Prevalence of Osteosarcoma
- Diagnosed Cases of Episodic and Chronic Osteosarcoma
Download the report to understand which factors are driving Osteosarcoma epidemiology trends @ Osteosarcoma Epidemiology Forecast
Osteosarcoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Osteosarcoma market or expected to get launched during the study period. The analysis covers Osteosarcoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Osteosarcoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Osteosarcoma Therapies and Key Companies
- Lenvatinib: Eisai
- Naxitamab: Y-mAbs Therapeutics
- BAY80-6946: Bayer
- Vactosertib: MedPacto
- Azenosertib: Zentalis Pharmaceuticals
- Surufatinib: Hutchmed
- Olaparib: AstraZeneca
- ZN-c3: Zentalis Pharmaceuticals
- Avelumab: Pfizer
- Lenvatinib: Merck Sharp & Dohme LLC
- OST31-164: George Clinical Pty Ltd
- Ifosfamide: Immunex/Berlex
- Pemetrexed: Eli Lilly and Company
- Calcium Folinate: Isofol Medical AB
- Nivolumab: Bristol-Myers Squibb
- RAD001: Novartis
- nhaled Lipid Cisplatin (ILC): Eleison Pharma
- Cisplatin: Genentech, Inc.
- ridaforolimus: Ariad Pharma
- Liposomal Vincristine: Inex Pharma
Discover more about therapies set to grab major Osteosarcoma market share @ Osteosarcoma Treatment Market
Osteosarcoma Market Strengths
- The rise in the incidence of osteosarcoma
- Improvement of treatment over the years along with newly updated guidelines
- Various immunotherapies such as PD-L1 inhibitors and CTLA4 inhibitors are under investigation for osteosarcoma
Osteosarcoma Market Opportunities
- Genetic and other disease-related biomarkers are not much explored in drug development
- Lack of approved drugs for chemo-resistant disease and maintenance therapy
Scope of the Osteosarcoma Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Osteosarcoma Companies: Eisai, Y-mAbs Therapeutics, Bayer, MedPacto, Zentalis Pharmaceuticals, Hutchmed, AstraZeneca, Pfizer, Merck Sharp & Dohme LLC, George Clinical Pty Ltd, Immunex/Berlex, Eli Lilly and Company, Isofol Medical AB, Bristol-Myers Squibb, Novartis, Eleison Pharma, Genentech, Inc., Ariad Pharma, Inex Pharma, and others
- Key Osteosarcoma Therapies: Lenvatinib, Naxitamab, BAY80-6946, Vactosertib, Azenosertib, Surufatinib, Olaparib, ZN-c3, Avelumab, Lenvatinib, OST31-164, Ifosfamide, Pemetrexed, Calcium Folinate, Nivolumab, RAD001, nhaled Lipid Cisplatin (ILC), Cisplatin, ridaforolimus, Liposomal Vincristine, and others
- Osteosarcoma Therapeutic Assessment: Osteosarcoma current marketed and Osteosarcoma emerging therapies
- Osteosarcoma Market Dynamics: Osteosarcoma market drivers and Osteosarcoma market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Osteosarcoma Unmet Needs, KOL’s views, Analyst’s views, Osteosarcoma Market Access and Reimbursement
To know more about Osteosarcoma companies working in the treatment market, visit @ Osteosarcoma Clinical Trials and Therapeutic Assessment
Table of Contents
1. Osteosarcoma Market Report Introduction
2. Executive Summary for Osteosarcoma
3. SWOT analysis of Osteosarcoma
4. Osteosarcoma Patient Share (%) Overview at a Glance
5. Osteosarcoma Market Overview at a Glance
6. Osteosarcoma Disease Background and Overview
7. Osteosarcoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Osteosarcoma
9. Osteosarcoma Current Treatment and Medical Practices
10. Osteosarcoma Unmet Needs
11. Osteosarcoma Emerging Therapies
12. Osteosarcoma Market Outlook
13. Country-Wise Osteosarcoma Market Analysis (2019–2032)
14. Osteosarcoma Market Access and Reimbursement of Therapies
15. Osteosarcoma Market Drivers
16. Osteosarcoma Market Barriers
17. Osteosarcoma Appendix
18. Osteosarcoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services